EICHORPublic-registry site landscape for NCT02718066, “Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer”, a Melanoma study sponsored by HUYABIO International, LLC.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02718066 (registry record) |
| Study title | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer |
| Official title | A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC) |
| Sponsor | HUYABIO International, LLC. |
| Condition(s) | Melanoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 6 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02718066.
Eichor generates a preliminary site-risk snapshot for NCT02718066 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Melanoma trials
← Eichor home · All tracked trials · Melanoma studies · Weekly briefs
